All Journals > Clinical Infectious Diseases > 15 August 2006 > Buprenorphine and HIV Clinical Care

Article Tools

Search for Related Articles

  • By Author
  • Search In

Announcements

CID LISTED AMONG
“MOST INFLUENTIAL”

Clinical Infectious Diseases has been named as one of the "100 Most Influential Journals in Biology and Medicine" of the past 100 years by the Special Libraries Association. The list was compiled by the 680-plus members of SLA’s Biomedical and Life Sciences Division.

See the full list here.

Source: The DBIO 100, the 100 Most Influential Journals in Biology & Medicine over the last 100 Years

In the News

Featured in MSNBC
"Germs and flu are up; infection control is down" June 9, 2009
Trends in the Incidence of Methicillin‐Resistant Staphylococcus aureus Infection in Children’s Hospitals in the United States
Jeffrey S. Gerber, Susan E. Coffin, Sarah A. Smathers, and Theoklis E. Zaoutis
Just this week, researchers reported that the incidence of MRSA infections among children admitted to pediatric hospitals in the United States more than tripled between 2002 and 2007. Researchers at the Children’s Hospital of Philadelphia and the University of Pennsylvania found cases of MRSA jumped from 6.7 per 1,000 admissions in 2002 to 21.1 cases per 1,000 admissions in 2007, according to a study released online Monday in the journal Clinical Infectious Diseases.

Featured in Toronto Star
"Pigs, viruses and politics" May 2, 2009
Are Swine Workers in the United States at Increased Risk of Infection with Zoonotic Influenza Virus?
Kendall P. Myers, Christopher W. Olsen, Sharon F. Setterquist, Ana W. Capuano, Kelley J. Donham, Eileen L. Thacker, James A. Merchant, and Gregory C. Gray
Another study, this one published in the U.S. journal Clinical Infectious Diseases in 2006, found that workers in meat-processing plants have a greater likelihood of being infected by some version of the H1N1 flu virus than the general population (the odds of pig farmers getting the disease are significantly greater again).

Featured in Philadelphia Inquirer
"A shot in the arm for vaccines" April 19, 2009
Vaccines: Pneumococcal Vaccination of Elderly Adults: New Paradigms for Protection
Lisa A. Jackson and Edward N. Janoff
Every year, an estimated 915,000 people 65 and older get pneumonia, and 40 percent of them end up in hospitals, according to a 2004 paper in the journal Clinical Infectious Diseases. Pneumonia often kills older people, said Richard Stefanacci, a geriatrician at the University of the Sciences in Philadelphia.

15 August 2006 Supplement

Volume 43, Number S4
Clinical Infectious Diseases 2006;43:S184–S190
© 2006 by the Infectious Diseases Society of America. All rights reserved.
1058-4838/2006/4312S4-0004$15.00
DOI: 10.1086/508182
SUPPLEMENT ARTICLE

A Trial of Integrated Buprenorphine/Naloxone and HIV Clinical Care

Lynn E. Sullivan,1

Declan Barry,2

Brent A. Moore,2

Marek C. Chawarski,2

Jeanette M. Tetrault,1

Michael V. Pantalon,2

Patrick G. O’Connor,1

Richard S. Schottenfeld,2 and

David A. Fiellin1

Departments of 1Internal Medicine and 2Psychiatry, Yale University School of Medicine, New Haven, Connecticut

Background.Untreated opioid dependence adversely affects the care of human immunodeficiency virus (HIV)–positive patients. Buprenorphine, a partial opioid agonist, is available for maintenance treatment of opioid dependence in HIV specialty settings. We investigated the feasibility and efficacy of integrating buprenorphine, along with 2 levels of counseling, into HIV clinical care.

Methods.HIV‐positive, opioid‐dependent patients were enrolled in a 12‐week pilot study and randomized to receive daily buprenorphine/naloxone treatment along with either brief physician management or physician management combined with nurse‐administered drug counseling and adherence management. Primary outcomes included treatment retention; illicit drug use, assessed by urine toxicology test and self‐report; CD4 lymphocyte counts; and log10 HIV type 1 (HIV‐1) RNA levels.

Results.Of the 16 patients who received at least 1 dose of buprenorphine, 13 (81%) completed 12 weeks of treatment. The proportion of opioid‐positive weekly urine test results decreased from 100% at baseline to 32% (month 1), 20% (month 2), and 16% (month 3). Only 4 patients reported any opioid use (in the prior 7 days) during the 12‐week study. CD4 lymphocyte counts remained stable over the course of the study. The mean log10 HIV‐1 RNA level (± standard deviation) declined significantly, from log10 HIV‐1 RNA copies/mL at baseline to log10 HIV‐1 RNA copies/mL at month 3 ( ). No significant differences based on counseling intervention were detected. All 13 patients who completed the study continued to receive treatment in an extension phase of at least 0–15 months' duration.

Conclusions.We conclude that it is feasible to integrate buprenorphine into HIV clinical care for the treatment of opioid dependence. Patients experienced good treatment retention and reductions in their opioid use. HIV biological markers remained stable or improved during buprenorphine/naloxone treatment.

Reprints or correspondence: Dr. Lynn E. Sullivan, Yale University School of Medicine, 333 Cedar St., PO Box 208025, New Haven, CT 06520‐8025 ().

Cited by

Kelly Brogan, Joseph Lux. (2009) Management of common psychiatric conditions in the HIV-positive population. Current HIV/AIDS Reports 6:2, 108-115
Online publication date: 1-Jun-2009.
CrossRef
David R. Bangsberg. (2008) Preventing HIV Antiretroviral Resistance through Better Monitoring of Treatment Adherence. The Journal of Infectious Diseases 197:s3, S272-S278
Online publication date: 15-May-2008.
Abstract-Full Text-PDF Version (187 kB)
Joseph Cofrancesco, Rebecca Scherzer, Phyllis C Tien, Cynthia L Gibert, Heather Southwell, Stephen Sidney, Adrian Dobs, Carl Grunfeld. (2008) Illicit drug use and HIV treatment outcomes in a US cohort. AIDS 22:3, 357-365
Online publication date: 1-Feb-2008.
CrossRef
Alexander Y Walley, Debbie M Cheng, Howard Libman, David Nunes, C Robert Horsburgh, Richard Saitz, Jeffrey H Samet. (2008) Recent drug use, homelessness and increased short-term mortality in HIV-infected persons with alcohol problems. AIDS 22:3, 415-420
Online publication date: 1-Feb-2008.
CrossRef
David A. Fiellin. (2007) The First Three Years of Buprenorphine in the United States: Experience to Date and Future Directions. Journal of Addiction Medicine 1:2, 62-67
Online publication date: 1-Jul-2007.
CrossRef
Lynn E. Sullivan, Robert D. Bruce, David Haltiwanger, Gregory M. Lucas, Lois Eldred, Ruth Finkelstein, and David A. Fiellin. (2006) Initial Strategies for Integrating Buprenorphine into HIV Care Settings in the United States. Clinical Infectious Diseases 43:s4, S191-S196
Online publication date: 15-Aug-2006.
Abstract-Full Text-PDF Version (82 kB)
Jag Khalsa, Francis Vocci, Frederick Altice, David Fiellin, and Veronica Miller. (2006) Introduction: Buprenorphine and HIV Primary Care: New Opportunities for Integrated Treatment. Clinical Infectious Diseases 43:s4, S169-S172
Online publication date: 15-Aug-2006.
Abstract-Full Text-PDF Version (67 kB)
Back to Top
Close Popup